Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours

Summary

A phase 1B/2A study to assess the safety, tolerability, pharmacokinetic and anti-tumoral activity of EXS21546 in combination with a PD-1 inhibitor in patients with advanced solid tumours.

Timeline

Start

2023-04-11

Primary completion

2023-09-27

Completion

2023-10-23

Outcome

Outcome not reported

Stopped: “Emerging data demonstrates challenge for EXS21546 to reach suitable therapeutic index.”

Drugs

Indications